North America Idiopathic Thrombocytopenic Purpura Therapeutics Market Size & Outlook
The idiopathic thrombocytopenic purpura therapeutics market in North America is expected to reach a projected revenue of US$ 349.7 million by 2030. A compound annual growth rate of 4.5% is expected of North America idiopathic thrombocytopenic purpura therapeutics market from 2024 to 2030.
- Pharmaceuticals
- Blood Disorders Treatment
- idiopathic thrombocytopenic purpura itp therapeutics
- Blood Disorders Treatment
Revenue, 2023 (US$M)
$257.5
Forecast, 2030 (US$M)
$349.7
CAGR, 2024 - 2030
4.5%
Report Coverage
North America
North America Idiopathic Thrombocytopenic Purpura Therapeutics Market, 2018-2030 (US$M)
Global Market
Related Markets
Prism AI by Grand View ResearchFree to try
Ask a question about the idiopathic thrombocytopenic purpura itp therapeutics market
Every figure cited from GVR research
North America idiopathic thrombocytopenic purpura therapeutics market highlights
- The North America idiopathic thrombocytopenic purpura therapeutics market generated a revenue of USD 257.5 million in 2023.
- The market is expected to grow at a CAGR of 4.5% from 2024 to 2030.
- In terms of segment, acute itp was the largest revenue generating disease type in 2023.
- Acute ITP is the most lucrative disease type segment registering the fastest growth during the forecast period.
North America data book summary
| Market revenue in 2023 | USD 257.5 million |
| Market revenue in 2030 | USD 349.7 million |
| Growth rate | 4.5% (CAGR from 2023 to 2030) |
| Largest segment | Acute itp |
| Fastest growing segment | Acute ITP |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Acute ITP |
| Key market players worldwide | Amgen Inc, Roche, Grifols SA Ordinary Shares - Class A, GSK PLC, Intromedic, Medtronic PLC, FUJIFILM Holdings Corp, Olympus Corp |
Other key industry trends
- In terms of revenue, North America region accounted for 39.7% of the global idiopathic thrombocytopenic purpura therapeutics market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 193.1 million by 2030.
No credit card required*
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Idiopathic Thrombocytopenic Purpura Itp Therapeutics
Idiopathic thrombocytopenic purpura itp therapeutics segmentation & scope
Product
Corticosteroids
IVIG
Anti-D Immunoglobulins
TPO-RA
Others
Idiopathic Thrombocytopenic Purpura Itp Therapeutics Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| Medtronic PLC | View profile | 95,000 | Lower Hatch Street, 20 On Hatch, Dublin, Ireland, 2 | www.medtronic.com |
| Olympus Corp | View profile | 33,629 | Shinjuku Monolith, 2-3-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan, 163-0914 | www.olympus.co.jp |
| FUJIFILM Holdings Corp | View profile | 83,784 | 7-3, Akasaka 9-chome, Minato-ku, Tokyo, Japan, 107-0052 | www.fujifilmholdings.com |
| GSK PLC | View profile | 70,200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | www.gsk.com |
| Intromedic | View profile | - | Seoul, Seoul-t'ukpyolsi, South Korea, Asia | www.intromedic.co.kr |
| Grifols SA Ordinary Shares - Class A | View profile | 23,737 | Avinguda de la Generalitat, 152, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, Spain, 08174 | www.grifols.com |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | www.roche.com |
North America idiopathic thrombocytopenic purpura itp therapeutics
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Idiopathic Thrombocytopenic Purpura Therapeutics Market Outlook will help companies and investors design strategic landscapes.
Acute Itp was the largest segment with a revenue share of 100.0% in 2023.
Horizon Databook has segmented the North America idiopathic thrombocytopenic purpura therapeutics market based on acute itp covering the revenue growth of each sub-segment from 2018 to 2030.
- North America Idiopathic Thrombocytopenic Purpura Therapeutics Market Disease Type Outlook (Revenue, USD Million , 2018-2030)
- Acute ITP
- Chronic
- Others
- North America Idiopathic Thrombocytopenic Purpura Therapeutics Market Product Outlook (Revenue, USD Million , 2018-2030)
- Corticosteroids
- IVIG
- Anti-D Immunoglobulins
- TPO-RA
- Others
Reasons to subscribe to idiopathic thrombocytopenic purpura itp therapeutics databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of idiopathic thrombocytopenic purpura itp therapeutics databook
- Our clientele includes a mix of idiopathic thrombocytopenic purpura itp therapeutics companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America idiopathic thrombocytopenic purpura itp therapeutics, including forecasts for subscribers. This continent databook contains high-level insights into North America idiopathic thrombocytopenic purpura itp therapeutics from 2018 to 2030, including revenue numbers, major trends, and company profiles.